JAGX ▼ -0.2% - Jaguar Health, Inc. $JAGX - Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting 29-SEP-2026 04:30 AM ET